MedTrace Logo

FDGal PET/CT to Detect Hepatocellular Carcinoma

NCT02899325 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-02-21

No results posted yet for this study

Summary

Liver cancer is one of the leading causes of cancer death among Asian men. If diagnosed early the disease is treatable with surgery. Current conventional imaging modalities have limitations to early detection. This study proposes to use 18F-FGal and 18F-FDG PET/CT scans to compare the clinical efficacy of diagnosing hepatocellular carcinoma (a type of liver cancer) using these PET/CT scans.

Conditions

Interventions

DRUG

Diagnostic PET/CT scans

These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.

Sponsors & Collaborators

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Francois Benard, MD · British Columbia Cancer Agency

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-10-31
Completion
2021-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02899325 on ClinicalTrials.gov